TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 ...

TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum ...

TransCode Therapeutics Inc : TransCode Therapeutics et Quantum Leap Healthcare Collaborative annoncent le lancement d'un essai clinique de phase 2a d'expansion de dose avec le TTX-MC138, à ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...

TransCode Therapeutics Inc. (RNAZ) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...

Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2 PK data from Cohorts ...

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate ...